CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Intranasal Methamphetaminedrug
Likely dose
Intranasal Methamphetamine 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03226223
NCT03226223Phase 2Completed
CompareCT.gov

Using Pharmacogenetics to Better Evaluate Naltrexone for Treating Stimulant Abuse

New York State Psychiatric Institute·interventional·Posted Jul 21, 2017·Updated Nov 24, 2020

In Brief

A Phase 2 clinical trial evaluating Intranasal Methamphetamine for Substance Use Disorders and Methamphetamine Abuse. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This investigation will be the first study assessing genetic modulation of naltrexone's NTX effects upon the abuse liability of a stimulant drug (methamphetamine). The study team will assess the ability of oral NTX to block the reinforcing and positive subjective effects of intranasal (IN) methamphetamine (30mg/70kg). This investigation could identify an important Gene x Pharmacological interaction, contributing to the personalization of stimulant abuse pharmacotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubstance Use Disorders, Methamphetamine Abuse
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 21, 2017
Enrollment StartSep 15, 2016
Primary CompletionJul 15, 2019
Study CompletionJul 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 8.9 years ago

Interventions

Intranasal Methamphetaminedrug

Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)